ABSTRACT
Formation of neutralizing antibodies (NAB) to alpha-interferon (aINF) was assessed in the reaction of antiviral activity neutralization in 36 children with severe juvenile respiratory papillomatosis (JRP). Surgical removal of papillomas was combined with administration of recombinant aINF preparations (reaferon, intron A, viferon). High and moderate neutralizing activity was determined in 22 (61.1%) patients. 7, 2 and 13 of them received reaferon, intron A and viferon, respectively. NAB were not registered in the rest 14 (38.9%) patients. The frequency of NAB formation was not related to the preparation used, only in the group on reaferon it was insignificantly higher. It was found that the highest response to therapy occurred in children with low NAB titer (8 of 12 children, 66.7%), while children with high NAB titer (3 of 4 children, 75%) did not respond.
Subject(s)
Antibodies/immunology , Antiviral Agents/immunology , Interferon-alpha/immunology , Laryngeal Neoplasms , Papilloma , Respiration Disorders/etiology , Adolescent , Antibody Formation , Child , Child, Preschool , Female , Humans , Laryngeal Neoplasms/complications , Laryngeal Neoplasms/drug therapy , Laryngeal Neoplasms/immunology , Male , Neutralization Tests , Papilloma/complications , Papilloma/drug therapy , Papilloma/immunology , Treatment OutcomeABSTRACT
Identification of the type of human papilloma virus (HPV) was done by means of polymerase chain reaction in 40 children with juvenile respiratory papillomatosis (JRP). Adjuvant to surgery interferon treatment was carried out in 18 patients (study group) with severe JRP. The rest 22 patients (control group) with less severe papillomatosis received only surgical treatment. The majority of the patients from both the groups had the virus type 6/11 (72.2 and 77.3% for the study and control groups, respectively). The assessment of a relationship between HPV type and effectiveness of interferon treatment in the study group has shown that the share of patients with effective and uneffective interferon therapy in each category (by HPV type) was about the same, i.e. no correlation exists between HPV type and interferon therapy effectiveness.
Subject(s)
Interferon Type I/therapeutic use , Laryngeal Neoplasms/drug therapy , Papilloma/drug therapy , Papillomaviridae/classification , Papillomavirus Infections/drug therapy , Tumor Virus Infections/drug therapy , Adolescent , Child , Child, Preschool , Drug Administration Routes , Drug Therapy, Combination , Female , Humans , Infant , Interferon Type I/administration & dosage , Interferon alpha-2 , Interferon-alpha , Laryngeal Neoplasms/pathology , Laryngeal Neoplasms/virology , Male , Neoplasm Recurrence, Local , Papilloma/pathology , Papilloma/virology , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , RNA, Viral/analysis , Recombinant Proteins , Treatment Outcome , Tumor Virus Infections/pathology , Tumor Virus Infections/virologySubject(s)
Sleep Apnea Syndromes/diagnosis , Child, Preschool , Humans , Male , Sleep Apnea Syndromes/surgery , TonsillectomyABSTRACT
The data obtained by foreign and national investigators on pathogenesis of congenital juvenile papillomatosis allow to confirm the existence of a congenital form of juvenile respiratory papillomatosis of the larynx.
Subject(s)
Laryngeal Neoplasms/congenital , Papilloma/congenital , Age Factors , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Laryngeal Neoplasms/diagnosis , Laryngoscopy , Male , Papilloma/diagnosis , Sex FactorsABSTRACT
Children with juvenile respiratory papillomatosis given alpha 2-INF had antibodies to alpha 2-INF in 67.7% of cases. In children treated with intramuscular recombinant alpha 2-INF (reaferon) alone antibodies to INF occurred in 92.3% of patients. The proportion of such patients fell to 28.5% if the children used recombinant alpha 2-INF as rectal suppositories viferon. The level of the antibodies in 4-48 hours decreased 2 times maximally and returned to the baseline on day 3 since intramuscular injection of alpha 2-INF. It is stated that interferon therapy had a positive effect on juvenile respiratory papillomatosis. Antibodies to INF had no negative effects on the treatment results.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Antibodies/analysis , Antineoplastic Agents/therapeutic use , Interferon Type I/therapeutic use , Interferons/immunology , Laryngeal Neoplasms/therapy , Papilloma/therapy , Adjuvants, Immunologic/administration & dosage , Adolescent , Antineoplastic Agents/administration & dosage , Child , Child, Preschool , Humans , Infant , Injections, Intramuscular , Interferon Type I/administration & dosage , Interferon alpha-2 , Interferon-alpha , Laryngeal Neoplasms/immunology , Papilloma/immunology , Recombinant Proteins , SuppositoriesABSTRACT
The authors tried a new medical form of interferon, rectal suppositories viferon, to treat severe juvenile respiratory papillomatosis in young children. Side effects were absent, antibodies to interferon in low titers were registered in 2 patients only. Further studies are needed to specify the promising effects of the above treatment.
